Pleural Effusion

Disclaimer: This information is intended for educational purposes and as a clinical reference for healthcare professionals. It is not a substitute for professional medical advice, diagnosis, or treatment. Clinical decisions must always be based on the individual patient's condition, available evidence, and the clinician's judgment. Always consult with a qualified healthcare professional for any health concerns or before making any decisions related to patient care.

---

Overview

• Definition: Pleural effusion is an abnormal accumulation of fluid in the pleural space, the potential space between the parietal and visceral pleurae surrounding the lungs. Normally, this space contains a small amount (approximately 10-20 mL) of lubricating fluid.
• Epidemiology:
  • Common clinical finding, estimated to affect over 1.5 million people annually in the United States.
  • Most common causes worldwide include congestive heart failure, pneumonia (parapneumonic effusion), malignancy, pulmonary embolism, and liver cirrhosis.
  • Malignant pleural effusion (MPE) is a significant cause, with lung cancer, breast cancer, and lymphoma being the most frequent primary tumors.
  • Incidence increases with age due to higher prevalence of underlying conditions.
• Classification:
  • Transudative Effusion: Results from imbalances in hydrostatic or oncotic pressures (e.g., heart failure, cirrhosis, nephrotic syndrome) where the pleural capillaries are intact. Characterized by low protein and low lactate dehydrogenase (LDH) levels.
  • Exudative Effusion: Results from inflammation or disease of the pleura itself, leading to increased capillary permeability or impaired lymphatic drainage (e.g., infection, malignancy, autoimmune disease, pulmonary embolism). Characterized by high protein and high LDH levels.
  • Specific Subtypes (Exudative):
    • Parapneumonic Effusion: Associated with bacterial pneumonia, lung abscess, or bronchiectasis. Can be uncomplicated, complicated, or empyema.
    • Malignant Pleural Effusion (MPE): Due to primary or metastatic cancer involving the pleura.
    • Tuberculous Pleural Effusion: Caused by Mycobacterium tuberculosis infection of the pleura.
    • Chylothorax: Accumulation of lymphatic fluid (chyle) in the pleural space, usually due to disruption of the thoracic duct.
    • Hemothorax: Presence of gross blood (hematocrit > 50% of peripheral blood) in the pleural space.
    • Urinothorax: Pleural effusion due to extravasated urine from a urinary tract obstruction or injury.
    • Other: Autoimmune diseases (e.g., lupus, rheumatoid arthritis), pancreatitis, drug-induced, asbestos exposure, post-cardiac injury syndrome.

Pathophysiology

• Mechanism:
  • Pleural fluid formation is primarily from parietal pleural capillaries and lymphatic drainage from the visceral pleura and parietal pleura. The balance between hydrostatic and oncotic pressures drives fluid movement.
  • Increased hydrostatic pressure: Seen in left ventricular failure leading to pulmonary venous hypertension, or systemic venous hypertension (e.g., right ventricular failure). Causes transudative effusion (e.g., congestive heart failure).
  • Decreased oncotic pressure: Due to low plasma protein levels (e.g., hypoalbuminemia in cirrhosis, nephrotic syndrome). Causes transudative effusion.
  • Increased capillary permeability: Inflammation or direct injury to the pleural capillaries allows proteins and fluid to leak into the pleural space. Causes exudative effusion (e.g., pneumonia, malignancy, inflammation).
  • Impaired lymphatic drainage: Obstruction of lymphatic vessels (e.g., by tumor cells, fibrosis) prevents reabsorption of fluid and protein. Causes exudative effusion (e.g., malignancy, chylothorax).
  • Movement of fluid from peritoneal cavity: Through diaphragmatic defects or lymphatics (e.g., ascites in cirrhosis, peritoneal dialysis). Can be transudative or exudative.
• Risk Factors:
  • Congestive heart failure
  • Chronic liver disease (cirrhosis with ascites)
  • Kidney disease (nephrotic syndrome, uremia)
  • Bacterial pneumonia, tuberculosis
  • Malignancy (lung, breast, lymphoma, ovarian, gastric, etc.)
  • Pulmonary embolism
  • Autoimmune diseases (rheumatoid arthritis, systemic lupus erythematosus)
  • Pancreatitis
  • Esophageal rupture
  • Trauma (chest injury)
  • Certain medications (e.g., amiodarone, methotrexate, nitrofurantoin, beta-blockers, phenytoin)
  • Asbestos exposure (benign asbestos effusion, mesothelioma)
  • Prior thoracic surgery or radiation
• Protective Factors: Generally, no specific "protective factors" exist against pleural effusion itself, as it is a manifestation of an underlying disease. Prevention focuses on managing or preventing the underlying conditions.

Clinical Presentation

Signs and Symptoms

• Cardinal Features:
  • Dyspnea: Most common symptom, often worse with exertion and lying flat. Severity correlates with effusion size, rate of accumulation, and underlying lung disease.
  • Pleuritic Chest Pain: Sharp, localized pain worsened by deep inspiration, coughing, or movement. Common with inflammatory effusions (e.g., parapneumonic, PE, malignancy). May be referred to the shoulder (diaphragmatic irritation).
  • Cough: Dry, non-productive cough due to bronchial irritation or compression.
• Early Signs:
  • Subtle dyspnea, particularly on exertion.
  • Mild, intermittent pleuritic pain.
  • Nonspecific fatigue.
• Advanced Signs:
  • Severe dyspnea at rest, orthopnea.
  • Absent or severely diminished breath sounds.
  • Tracheal deviation (with very large effusions).
  • Hypoxia.
  • Signs of the underlying disease (e.g., weight loss and cachexia in malignancy, fever and chills in infection, peripheral edema in heart failure).
• Atypical Presentations:
  • Asymptomatic, discovered incidentally on imaging (common with small effusions or transudates).
  • Shoulder pain without typical pleuritic chest pain.
  • Abdominal pain (e.g., in pancreatitis with sympathetic effusion).
  • Signs of acute respiratory distress if effusion develops rapidly or is very large.

Physical Examination

• Inspection:
  • Reduced movement or lag on the affected side during respiration.
  • Asymmetry of the chest wall.
  • Tracheal deviation away from the effusion (in massive effusions, >1500 mL).
• Palpation:
  • Decreased or absent tactile fremitus over the effusion.
  • Tracheal deviation.
  • Apical impulse displacement (if significant left-sided effusion).
• Percussion:
  • Dullness or flatness over the effusion (distinct from hyperresonance of pneumothorax). The upper border of dullness forms a curving line (Ellis-Damoiseau curve).
• Auscultation:
  • Diminished or absent breath sounds over the effusion.
  • Bronchial breath sounds may be heard immediately above the effusion (due to compressed lung).
  • Egophony ("E" sounds like "A") immediately above the effusion.
  • Pleural friction rub (rare, indicates inflamed pleural surfaces usually without significant fluid, or resolving effusion).
• Special Tests: No specific "special tests" for pleural effusion itself beyond the standard physical exam. Focus is on identifying the signs described.

Diagnostic Approach

History Taking

• Key Questions:
  • Onset and duration: Acute vs. chronic accumulation.
  • Associated symptoms: Dyspnea (onset, severity, exertion), chest pain (character, location, radiation, relation to breathing/coughing), cough (productive/non-productive, sputum characteristics), fever/chills, night sweats, weight loss, hemoptysis.
  • Comorbidities: History of heart failure, liver disease, kidney disease, malignancy, autoimmune disorders, recent infections (pneumonia, TB exposure), trauma, pancreatitis.
  • Medications: Including over-the-counter and illicit drugs.
  • Occupational/environmental exposures: Asbestos, silica.
  • Travel history: Endemic areas for TB or fungal infections.
  • Social history: Smoking, alcohol use, IV drug use.
  • Prior medical procedures: Thoracic surgery, central line placement.
• Red Flags:
  • Acute onset severe dyspnea.
  • Hemodynamic instability (hypotension, tachycardia).
  • Hypoxia (SpO2 <90%).
  • Rapidly accumulating effusion.
  • Clinical suspicion of empyema (high fever, chills, purulent sputum).
  • Massive effusion causing tracheal deviation.

Laboratory Tests

• First-Line:
  • Diagnostic Thoracentesis with Pleural Fluid Analysis: Indicated for most new effusions > 1 cm on lateral decubitus CXR or > 0.5 cm on ultrasound (unless clear transudate from CHF responsive to diuresis).
    • Gross appearance: Color, clarity, odor. (e.g., straw-colored, purulent, sanguineous, milky, turbid).
    • Cell count with differential: Total nucleated cells, red blood cells, neutrophils, lymphocytes, eosinophils, mesothelial cells.
    • Protein: Pleural fluid protein.
    • Lactate Dehydrogenase (LDH): Pleural fluid LDH.
    • Glucose: Pleural fluid glucose.
    • pH: Pleural fluid pH (measured with blood gas analyzer, not litmus paper).
    • Cytology: For malignant cells.
    • Microbiology: Gram stain, bacterial culture, acid-fast bacilli (AFB) stain, mycobacterial culture, fungal culture (if indicated).
  • Simultaneous Serum Samples: For protein, LDH, and glucose to apply Lights Criteria.
• Confirmatory:
  • Lights Criteria (to differentiate transudate vs. exudate; if any one criterion is met, it's an exudate):
    1. Pleural fluid protein / Serum protein ratio > 0.5
    2. Pleural fluid LDH / Serum LDH ratio > 0.6
    3. Pleural fluid LDH > 2/3 upper limit of normal for serum LDH.
  • Specific Exudate Markers:
    • Adenosine Deaminase (ADA): Elevated in TB pleurisy (typically >40 U/L, higher in endemic areas).
    • Amylase: Elevated in pancreatitis, esophageal rupture, or malignancy.
    • Triglycerides: Elevated in chylothorax (>110 mg/dL, often >200 mg/dL). Cholesterol > 200 mg/dL suggests pseudochylothorax.
    • NT-proBNP: Helpful in diagnosing CHF-related effusion in ambiguous cases (often >1500 pg/mL).
    • Cholesterol: Pleural fluid cholesterol > 45 mg/dL suggests exudate.
    • Rheumatoid factor (RF), Anti-nuclear antibody (ANA): If autoimmune etiology suspected.
  • Empyema Criteria: Purulent fluid, positive Gram stain/culture, pleural fluid pH < 7.20, pleural fluid glucose < 60 mg/dL.
• Monitoring:
  • Not typically used for monitoring the effusion itself, but for the underlying disease (e.g., CBC, CRP for infection; cardiac biomarkers for CHF; tumor markers for malignancy).
  • Repeat thoracentesis may be performed to assess response to therapy or for recurrence.

Imaging

• Recommended:
  • Chest X-ray (CXR):
    • Initial screening test.
    • Blunting of costophrenic angle on PA view requires ~175-200 mL of fluid.
    • Blunting on lateral view requires ~75-100 mL.
    • Large effusions cause homogeneous opacification, obscuring diaphragm and heart border, with meniscus sign.
    • Lateral decubitus views are essential for detecting small effusions (>1 cm fluid layer) and for guiding thoracentesis.
  • Thoracic Ultrasound (TUS):
    • Highly sensitive for detecting small effusions (as little as 5-10 mL).
    • Distinguishes free fluid from loculated fluid.
    • Identifies septations, fibrin strands, or pleural thickening.
    • Crucial for guiding thoracentesis safely, minimizing complications.
• Advanced:
  • Computed Tomography (CT) of the Chest with Contrast:
    • Provides detailed anatomical information.
    • Helps characterize pleural abnormalities (nodules, masses, thickening).
    • Identifies associated parenchymal lung disease, mediastinal lymphadenopathy, or abdominal pathology contributing to the effusion.
    • Useful for distinguishing empyema (e.g., split pleura sign) from lung abscess.
    • Recommended for all undiagnosed exudative effusions.
  • Magnetic Resonance Imaging (MRI): Less commonly used than CT for initial evaluation, but can be helpful in specific cases (e.g., differentiating benign from malignant pleural thickening, especially near the diaphragm or spinal canal).
  • Positron Emission Tomography-CT (PET-CT): Useful in suspected malignant effusion to identify primary tumor, metastatic sites, and assess metabolic activity of pleural lesions.
  • Medical Thoracoscopy (Pleuroscopy/VATS): Direct visualization of the pleural space, allowing for targeted biopsies and therapeutic interventions (e.g., talc pleurodesis). Indicated for undiagnosed exudative effusions after initial workup, especially when malignancy or TB is suspected.

Management

Acute Management

• Immediate:
  • Assess airway, breathing, circulation (ABCs).
  • Provide supplemental oxygen if hypoxic (SpO2 <90%).
  • Obtain vascular access.
  • Therapeutic Thoracentesis: For symptomatic relief of dyspnea caused by large effusion. Typically, 1.0-1.5 liters can be safely removed, with caution to avoid re-expansion pulmonary edema. No maximum volume, but consider stopping if patient develops chest pain, cough, or symptoms of re-expansion pulmonary edema.
• Stabilization:
  • Monitor vital signs and oxygen saturation closely.
  • Address the underlying cause if immediately identifiable and treatable (e.g., diuretics for severe CHF exacerbation).
  • Pain management (e.g., NSAIDs for pleuritic pain).
• Emergency:
  • Massive Effusion with Mediastinal Shift: Immediate large-volume therapeutic thoracentesis to relieve compression and prevent cardiovascular compromise.
  • Tension Hydrothorax (rare): Very large effusion causing obstructive shock; requires urgent drainage.
  • Empyema: Requires urgent drainage (chest tube insertion) and antibiotics.

Chronic Management

• Pharmacological:
  • Diuretics: For transudative effusions due to heart failure, cirrhosis, or nephrotic syndrome (e.g., Furosemide, Spironolactone).
  • Antibiotics: For parapneumonic effusions or empyema. Empiric broad-spectrum coverage initially (e.g., Beta-lactam/beta-lactamase inhibitor like Piperacillin-Tazobactam or Ceftriaxone + Metronidazole), then tailored to culture results. Duration typically 2-4 weeks.
  • Anti-tuberculous drugs: For tuberculous pleurisy (e.g., RIPE therapy: Rifampin, Isoniazid, Pyrazinamide, Ethambutol). Typically for 6 months.
  • Chemotherapy/Immunotherapy: For malignant pleural effusions, targeting the underlying cancer.
  • Anti-inflammatory/Immunosuppressants: For effusions due to autoimmune diseases (e.g., corticosteroids, methotrexate).
• Non-pharmacological:
  • Therapeutic Thoracentesis (repeated): For symptomatic recurrent effusions, especially in palliative care settings (e.g., malignant effusion).
  • Pleurodesis: Inducing chemical (e.g., talc slurry, doxycycline) or mechanical fusion of the parietal and visceral pleura to prevent reaccumulation of fluid. Indicated for symptomatic recurrent malignant effusions when life expectancy is >1-3 months.
    • Talc pleurodesis: Most effective agent. Administered via chest tube or during thoracoscopy. Dosing: 4-5 grams sterile talc slurry.
  • Indwelling Pleural Catheter (IPC): A tunneled catheter inserted into the pleural space for intermittent drainage by the patient or caregiver at home. Preferred for symptomatic recurrent effusions with limited life expectancy (<1-3 months) or poor performance status, or when pleurodesis has failed or is contraindicated.
  • Surgical Interventions:
    • Video-Assisted Thoracoscopic Surgery (VATS): For diagnosis (biopsy) and therapeutic interventions (e.g., decortication for trapped lung in chronic empyema, mechanical pleurodesis, fenestration).
    • Pleuroperitoneal Shunt: Rarely used, for highly refractory malignant effusions.
• Monitoring:
  • Clinical assessment of dyspnea and pain.
  • Repeat imaging (CXR, ultrasound) to assess fluid reaccumulation.
  • Monitoring of underlying disease treatment response.

Treatment Algorithms

• First-Line:
  1. Identify presence of effusion and quantify: CXR, Ultrasound.
  2. Determine etiology (transudate vs. exudate): Thoracentesis with Lights Criteria, serum labs.
  3. Treat underlying cause:
     • Transudate: Manage heart failure (diuretics, fluid restriction), liver cirrhosis (diuretics, paracentesis for ascites), nephrotic syndrome (protein replacement, steroids).
     • Exudate:
       • Parapneumonic: Antibiotics. If complicated (pH < 7.20, glucose < 60, positive Gram stain/culture, loculated fluid), consider chest tube drainage.
       • Empyema: Urgent chest tube drainage + antibiotics. May require fibrinolytics (e.g., alteplase) if loculated, or VATS decortication for trapped lung.
       • Malignant: Manage underlying cancer (chemotherapy, radiation). For symptomatic relief of effusion, consider therapeutic thoracentesis, IPC, or pleurodesis.
       • Tuberculous: Anti-tuberculous chemotherapy.
       • Chylothorax: Low-fat diet with medium-chain triglycerides, total parenteral nutrition, thoracic duct embolization, or surgical ligation of thoracic duct.
• Second-Line:
  • Refractory Transudates: Consider pleurodesis in highly symptomatic cases (rare).
  • Complicated Parapneumonic/Empyema: Fibrinolytic therapy via chest tube (e.g., Alteplase 4 mg in 50 mL saline, followed by Dornase alfa 5 mg in 30 mL saline, instilled twice daily for 3 days), or surgical decortication (VATS).
  • Recurrent Malignant Effusion: IPC, pleurodesis (chemical/mechanical).
• Refractory Cases:
  • For persistent symptomatic malignant effusions despite pleurodesis: IPC is the preferred option.
  • For chronic empyema with trapped lung despite chest tube and fibrinolytics: VATS decortication.
  • For highly refractory chylothorax: Thoracic duct ligation.

Complications

• Common:
  • Dyspnea: Persistent or recurrent despite drainage.
  • Pleuritic Chest Pain.
  • Cough: Often post-drainage.
  • Re-expansion Pulmonary Edema: Rare but serious complication after rapid or large volume drainage (>1.5 liters), especially in chronic effusions. Symptoms include cough, chest tightness, dyspnea, hypoxemia.
  • Pneumothorax: Iatrogenic, typically post-thoracentesis.
  • Bleeding: Due to vessel puncture during thoracentesis.
  • Infection: Post-procedure empyema (rare).
• Serious:
  • Empyema: Frank pus in the pleural space, or positive Gram stain/culture, pH < 7.20, glucose < 60 mg/dL.
  • Trapped Lung: Lung unable to re-expand due to fibrinous peel on the visceral pleura, often a sequela of chronic inflammation (e.g., empyema, TB).
  • Bronchopleural Fistula: Abnormal connection between bronchus and pleural space, leading to persistent air leak and risk of empyema.
  • Hemothorax: Significant bleeding into the pleural space, potentially leading to hypovolemic shock.
  • Mediastinal Shift and Cardiorespiratory Compromise: With massive effusions.
• Long-term:
  • Chronic pleuritic pain.
  • Pleural thickening and fibrosis, potentially causing restrictive lung disease.
  • Recurrence of effusion.
  • Impact on quality of life due to persistent symptoms or need for ongoing drainage/management.

Prognosis

• Factors:
  • Underlying etiology: This is the most significant determinant.
    • Transudates (e.g., CHF) generally have a good prognosis related to management of the primary condition.
    • Malignant pleural effusion implies advanced cancer and generally poor prognosis (median survival typically 3-12 months depending on primary cancer type and extent).
    • Empyema: Prognosis depends on timely drainage and appropriate antibiotic therapy.
    • Tuberculous pleurisy: Excellent prognosis with appropriate antituberculous treatment.
  • Extent and rapidity of fluid accumulation.
  • Patient's overall health and comorbidities.
  • Response to treatment.
• Survival: Highly variable.
  • CHF-related effusions: Determined by CHF severity and management.
  • Malignant effusions: Median survival can be as low as 3-4 months for lung cancer or mesothelioma, longer for breast cancer or lymphoma (6-12 months).
  • Empyema: Mortality up to 20% in severe cases if not adequately managed.
• Quality of Life:
  • Significantly impacted by persistent dyspnea, pain, and the need for repeated interventions (thoracentesis, IPC drainage).
  • Depends on the burden of the underlying disease.
  • Palliative care plays a crucial role in improving quality of life for patients with malignant effusions.

Prevention

• Primary: Aimed at preventing the underlying conditions that lead to effusion.
  • Heart failure: Optimal management of hypertension, coronary artery disease, valvular heart disease.
  • Liver cirrhosis: Management of chronic viral hepatitis, alcohol abstinence.
  • Infections: Vaccination (pneumococcal, influenza), prompt treatment of pneumonia.
  • Malignancy: Smoking cessation, early detection programs where available.
• Secondary: Early diagnosis and intervention to prevent progression or complications.
  • Prompt investigation of new-onset dyspnea or chest pain.
  • Timely diagnostic thoracentesis.
  • Aggressive management of complicated parapneumonic effusions to prevent empyema.
• Tertiary: Preventing complications and recurrence.
  • Appropriate management of empyema (drainage, antibiotics, decortication if needed).
  • Effective pleurodesis or IPC for recurrent symptomatic malignant effusions.
  • Careful therapeutic thoracentesis to minimize risk of re-expansion pulmonary edema.

Special Populations

• Pediatric:
  • Less common than in adults.
  • Causes differ: Parapneumonic effusions are most common, often leading to empyema. Other causes include congenital heart disease, nephrotic syndrome, pancreatitis, malignancy (e.g., lymphoma, neuroblastoma).
  • Diagnosis and management principles similar, but volumes for drainage and drug dosages must be weight-based.
  • Ultrasound guidance for thoracentesis is crucial.
• Geriatric:
  • Higher prevalence due to increased burden of comorbidities (CHF, malignancy, chronic kidney disease).
  • Atypical presentations are more common (e.g., less prominent pain).
  • Increased risk of complications from procedures (e.g., bleeding, pneumothorax) due to frailty, coagulopathies, or concurrent medications.
  • Careful assessment of functional status and goals of care is paramount when deciding on invasive procedures.
• Pregnancy:
  • Rare.
  • Causes: Cardiac decompensation, pulmonary embolism, preeclampsia/eclampsia, rarely malignancy.
  • Diagnostic imaging should minimize radiation exposure (ultrasound preferred, CXR with abdominal shielding if necessary, CT only if essential and benefits outweigh risks).
  • Management of underlying condition is key. Thoracentesis can be performed if symptomatic, with caution.
• Comorbidities:
  • Renal Failure: Can cause transudative effusion due to fluid overload, or exudative due to uremic pleuritis. Management needs to consider fluid status and dialysis schedule.
  • Immunocompromised: Higher risk of atypical infections (e.g., fungal, mycobacterial, Pneumocystis), leading to exudative effusions. Broad-spectrum empiric therapy may be needed.
  • Malignancy: Pleural effusion often indicates advanced disease. Management focuses on palliation of symptoms and improving quality of life.

Clinical Pearls

• Diagnostic:
  • Always perform a diagnostic thoracentesis for a new, unexplained pleural effusion unless it is a clear-cut transudate due to CHF that responds to diuretics.
  • Lights Criteria are key for classifying effusions into transudate or exudate, guiding further workup.
  • Ultrasound is your friend: Essential for identifying small effusions, loculations, and guiding safe thoracentesis.
  • Think globally for exudates: Malignancy, infection (parapneumonic, TB), and autoimmune are common, but consider rarer causes if initial workup is negative.
  • Pleural fluid pH is critical: Especially for parapneumonic effusions; a pH < 7.20 often dictates drainage.
  • Cytology is crucial for malignancy: Send enough fluid (minimum 50-60 mL) and ensure proper handling by pathology. Repeat cytology can increase diagnostic yield.
• Treatment:
  • Treat the underlying cause: The effusion is often a symptom, not the disease.
  • Symptomatic relief is important: Don't hesitate to drain large effusions causing dyspnea.
  • Don't over-drain: While there's no fixed volume limit, stopping if patient coughs or has chest pain can prevent re-expansion pulmonary edema.
  • Empyema requires prompt drainage: It's a surgical emergency in many cases; don't delay chest tube insertion.
  • Consider IPC early in recurrent MPE: Especially for patients with limited life expectancy or poor performance status; it offers better quality of life than repeated thoracentesis.
  • Talc pleurodesis is effective: For long-term control of MPE in suitable candidates.
• Pitfalls:
  • Misinterpreting a transudate as an exudate: Can lead to unnecessary investigations. Always use Lights Criteria with simultaneous serum labs.
  • Delaying drainage of empyema: Can lead to loculation, trapped lung, and increased morbidity/mortality.
  • Missing less common causes: Such as drug-induced, asbestos-related, or pancreatic effusions.
  • Not obtaining sufficient pleural fluid for diagnosis: Especially for cytology or AFB cultures.
  • Performing thoracentesis without ultrasound guidance: Increases risk of complications (pneumothorax, organ injury).
  • Not addressing severe pain: Patients can be very uncomfortable.

Recent Updates

• Guidelines:
  • American Thoracic Society (ATS) and European Respiratory Society (ERS) periodically update guidelines for various aspects of pleural disease, including management of malignant pleural effusions and parapneumonic effusions/empyema. Recent updates emphasize the role of IPCs and improved algorithms for complicated parapneumonic effusions.
• Evidence:
  • Growing evidence supporting the early use of IPCs in symptomatic malignant pleural effusion, offering comparable symptom control to pleurodesis, often with a better patient experience and fewer inpatient days.
  • Studies on the use of intrapleural fibrinolytics and DNAse (e.g., Alteplase and Dornase alfa) have shown benefit in improving drainage and reducing surgical referral rates for complicated parapneumonic effusions and empyema.
  • Research into novel therapeutic agents for malignant pleural effusions, including targeted therapies and immunotherapies, is ongoing, often administered systemically rather than intrapleurally.
  • Increased recognition and utility of thoracic ultrasound as an indispensable tool for diagnosis, characterization, and procedural guidance.
• Controversies:
  • Optimal timing for IPC vs. pleurodesis in malignant pleural effusion: While IPC is gaining favor for many, pleurodesis remains a viable option for those with longer life expectancy and good performance status.
  • Role of medical thoracoscopy: While highly diagnostic, its availability and cost-effectiveness are debated compared to less invasive methods.
  • Management of benign recurrent effusions: The role of IPCs in non-malignant recurrent effusions is still evolving.

Key References

• Guidelines:
  • Light, R. W. (2002). Pleural effusion. The New England Journal of Medicine, 346(25), 1971-1977. (Classic reference for Lights Criteria).
  • Gary, W. (2018). Management of malignant pleural effusions. UpToDate. (Regularly updated, comprehensive review).
  • Davies, H. E., et al. (2010). Management of pleural infection in adults: British Thoracic Society Pleural Disease Guideline 2010. Thorax, 65(Suppl 2), ii41-ii53. (Though older, principles remain relevant, updated by ATS/ERS).
  • American Thoracic Society and European Respiratory Society Statement on Pleural Procedures (e.g., Chest Tube Insertion, Thoracentesis Guidelines).
• Studies:
  • PACE trial (A randomized trial comparing IPC vs. talc pleurodesis for malignant pleural effusion, published in The Lancet or NEJM).
  • MIST2 trial (Multicenter Intrapleural Sepsis Trial 2), demonstrating the efficacy of intrapleural fibrinolytics and DNAse for pleural infection, published in NEJM.
• Reviews:
  • Porcel, J. M., & Light, R. W. (2013). Pleural effusions: diagnosis and management. Respirology, 18(2), 251-262.
  • J. M. Porcel, Current challenges in the management of pleural diseases. European Respiratory Review, 2020.
  • Textbooks: Murray & Nadel's Textbook of Respiratory Medicine, Fishman's Pulmonary Diseases and Disorders.